The relative risks were 0.541 ( 95 % confidence interval [ CI ] 0.308-0 .956 ; p = 0.03 ) for gadolinium-enhancing lesions ( the primary endpoint ) , 0.364 ( 95 % CI 0.207-0 .639 ; p = 0.001 ) for new and enlarging T2-hyperintense lesions , and 0.149 ( 95 % CI 0.046-0 .416 ; p = 0.001 ) for new T1-hypointense lesions .